Tuberulosis Therapy Effective in CKD PatientsRenal and Urology NewsIn a 12-month study of 572 CKD patients, of whom 33 had tuberculosis (TB), researchers in India found that 84.8% of subjects responded to ATT, although the responses to the treatment we…
Cricket365.com'My lung capacity has gone for a toss'Cricket365.comI know it is a hard and long way ahead. But I am happy with the way I started with the big ton against Central Zone," said Singh. "It will be a dream to play Test crick…
Smoking ups death risk in stroke survivorsTimes of IndiaThey followed them for 10 years, using medical records and in-person and telephone interviews, and tracked demographics, deaths, recurrent strokes and heart attacks. They found that compared to th…
Faeces transplant found to beat Clostridium Difficile in 90% of cases.
Faeces transplant found to beat Clostridium Difficile in 90% of cases.
Boston Scientific reports positive data from long coronary lesions trialEquities.comOct 26, 2012 (Datamonitor via COMTEX) — Boston Scientific Corporation has reported clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive o…
Cambridge NewsCan you help save Zoe's life?Cambridge NewsDoctors are currently treating Zoe with anti-thymocyte globulin (ATG) – an infusion of horse antibodies. However, it will be four months before Zoe will learn whether this has been successf…
Benlysta will be lupus market leader in 2021 with sales of more than $1.7 …The Pharma LetterThe off-label use of two high-priced agents – the biologic rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera) and the immu…
NDTVIKEA furniture to retain Scandinavian style in IndiaNDTVThe furniture retailer, which has grown into a global giant from its small-town roots in the heart of southern Sweden, is seeking new markets, with India on its horizon. Even there IKEA – know…
Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third QuarterBusiness Wire (press release)Approved and investigational therapies in Biogen Idec's MS franchise presented at the conference included BG-12, daclizumab-HYP, anti-LINGO, TY…